Editor-in-Chief:Binghe Xu, MD, PhD.


Dr. Binghe Xu is Professor and Director of the Breast Cancer Section, Department of Medical Oncology, and Vice Chairman of the Department of Medical Oncology at the Cancer Hospital and Institute, Chinese Academy of Medical Sciences (CAMS), and Peking Union Medical College (PUMC) in Beijing, China He received his Doctorate of Philosophy and Master of Science degree in oncology from the Peking Union Medical College, and his Doctorate of Medicine from Wuhan University Medical College in Hubei, China.

Dr. Xu has been committed to breast cancer research and clinical trials of new anticancer agents for more than 20 years, helped found Center of Breast Cancer, Cancer Hospital and Lab.of Clinical Pharmacology, New Drug Evaluation Center of Cancer Hospital, CAMS. His major interests are in basic and clinical research of breast cancer, multidisciplinary cancer treatments, clinical study of new anticancer agents. Dr. Xu have participated more than 60 clinical trials as PI, currently, he is the executive steering committee (EC) and steering committee (SC) members of several global clinical trials. 

Dr. Xu has published 210 papers in peer reviewed oncology journals, including “Cancer Research”, “Journal of Clinical Oncology”,,“Clinical Cancer Research”, mainly with respect to breast diseases, clinical trials of anticancer agents and multi-drug resistance. As a chief editor, he published 《Breast Cancer》, a book by Peking University Medical Publisher in 2005.

Dr. Xu has served on the editorial boards of 16 journals including The International Journal of Biological Markers, Chinese Journal of Cancer Research, Chinese Journal of Cancer, Experimental Hematology & Oncology. He is the several current society members, including: Vice Chairman., Chinese Society of Breast Cancer (CSBC); Member of American Society of Clinical Oncology (ASCO); Member of  Pharmacopoeia Commission of People's Republic of China (ChPC).

Selected Papers (SCI) in recent four years: 
  1. Dianke Yu, Xuemei Zhang, Ju Liu, Peng Yuan, Wen Tan, Yongli Guo, Tong Sun, Dan Zhao, Ming Yang, Junniao Liu, Binghe Xu*. Characterization of functional excision repair cross-complementation group 1 variants and their association with lung cancer risk and prognosis. Clin Cancer Res, 2008,14(9):2878-2886. 
  2. Zhonghua Wang, Binghe Xu*，Dongxin Lin, Wen Tan,Shiangjiin Leaw, Xiaonan Hong, Xichun Hu. XRCC1 polymorphisms and severe toxicity in lungcancer patients treated with cisplatin-basedchemotherapy in Chinese population. Lung Cancer, 2008, 62, 99-104. Xu BH*. Epothilones in the treatment of breast cancer: Review of clinical experience. Asia-Pac J Clin Oncol, 2008, 4(Suppl 3):S30-S39.
  3. Fei Ma, Tong Sun, Yuankai Shi, Dianke Yu, Wen Tan, Ming Yang, Chen Wu, Datong Chu ,Yan Sun, Binghe Xu*, Dongxin Lin. Polymorphisms of EGFR predict clinical outcome in advanced non-small-cell lung cancer patients treated with Gefitinib. Lung Cancer, 2009,66:114-119. 
  4. Yao S, Xu B*, Ma F, Liao Y & Fan Y. Breast Cancer in women younger than 25: clinicopathological features and prognostic factors. Ann Oncol, 2009, 20(2):387-389. 
  5. Chen Wu, Binghe Xu*, Peng Yuan, Jurg Ott, Yin Guan, Yu Liu, Zhe Liu,Yuanyuan Shen, Dianke Yu and Dongxin Lin. Genome-wide examination of genetic variants associatedwith response to platinum-based chemotherapy in patients with small-cell lung cancer. Pharmacogenetics and Genomics 2010, 20(6):389-395. 
  6. Jiayu Wang, Ying Fan, Binghe Xu*. Ixabepilone plus capecitabine for Chinese patients with metastatic breast cancer progressing after anthracycline and taxane treatment. Cancer Chemother Pharmacol, 2010, 66:597-603. 
  7. Ying Fan, Binghe Xu*, Yuqian Liao, Shuyang Yao, Yan Sun. A retrospective study of metachronous and synchronous ipsilateral supraclavicular lymph node metastases in breast cancer patients. Breast, 2010, 19:365-369. 
  8. Ying Fan, Binghe Xu*, Peng Yuan, Jiayu Wang, Fei Ma, Qing Li, Pin Zhang, Qiao Li, Ruigang Cai. Prospective Study of Vinorelbine and Capecitabine Combination Therapy in Chinese Patients with Metastatic Breast Cancer Pretreated with Anthracyclines and Taxanes. Chemotherapy 2010, 56:340–347. 
  9. Wu C, Xu B*, Yuan P, Miao X, Liu Y, Guan Y, Yu D, Xu J, Zhang T, Shen H, Wu T, Lin D. Genome-wide interrogation identifies YAP1 variants associated with survival of small-cell lung cancer patients. Cancer Res. 2010, 70(23):9721-9. 
  10. Peng Yuan, Li Liu, Chen Wu, Rong Zhong, Dianke Yu, Jing Wu, Yihua Xu, Shaofa Nie, Xiaoping Miao, Yan Sun, Binghe Xu* and Dongxin Lin. No association between XRCC1 polymorphisms and survival in non-small-cell lung cancer patients treated with platinum-based chemotherapy. Cancer Biology & Therapy, 2010, 10(9):854-859. 
  11. Binghe Xu*, Zhenzou Shen, Zefei Jiang, Zhongzhen Guan, Xiaoqing Zhang. A Phase II Study of Gemcitabine Plus Paclitaxel in Patients with Metastatic Breast Cancer and Prior Anthracycline Treatment. Asia-Pac J Clin Oncol, 2010, 6(4): 320-329.
  12. Joseph A. Sparan, Edyard Vrdoljak, Oliver Rixe, Binghe Xu, et al. Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol, 2010, 28(20):3256-3263.
  13. Gabriel N. Hortobagyi, Henry L. Gomez, Rubi K. Li, Hyun-Cheol Chung, Luis E. Fein, Valorie F. Chan, Jacek Jassem, Guillermo L. Lerzo, Xavier B. Pivot, Fernando Hurtado de Mendoza, Binghe Xu, Linda T. Vahdat, Ronald A. Peck, Pralay Mukhopadhyay and Henri H. Roché. Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes. Breast Cancer Res Treat, 2010，122：409－418.
  14. Binghe Xu*，Zefei Jiang， Zhimin Shao，Jiayu Wang， Jifeng Feng， Shuping Song， Zhendong Chen，Kangsheng Gu， Shiying Yu， Yiping Zhang，Chuan Wang， Fengchun Zhang，  Junlan Yang. Fulvestrant 250 mg versus anastrozole for Chinese patients with advanced breast cancer: results of a multicentre, double-blind, randomised phase III trial. Cancer Chemother Pharmacol. 2011, 67:223–230.
  15. Zhang P, Sun M, Qiu R, Tang L, Dou G, Xu B*. Phase I clinical and pharmacokinetic study of UTD1, a genetically engineered epothilone analog in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2011, 68:971-978. 
  16. BingHe Xu*, YiLong Wu, Lin Shen,  DingWei Ye,  Annette Jappe, Azzeddine Cherfi,  Hui Wang,  RuiRong Yuan. Two-dose-level confirmatory study of the pharmacokinetics and tolerability of everolimusin Chinese patients with advanced solid tumors. J Hematol Oncol, 2011, 4(1):3-6.
  17. Kaklamani VG, Xu BH, Gomez HL. Global experience with ixabepilone in breast cancer. Expert Rev Anticancer Ther. 2011 May;11(5):683-92.
  18. Roché H, Conte P, Perez EA, Sparano JA, Xu B, Jassem J, Peck R, Kelleher T, Hortobagyi GN. Ixabepilone plus capecitabine in metastatic breast cancer patients with reduced performance status previously treated with anthracyclines and taxanes: a pooled analysis by performance status of efficacy and safety data from 2 phase III studies. Breast Cancer Res Treat., 2011, 125(3):755-65.
  19. Bing-He Xu*, Ze-Fei Jiang, Daniel Chua, Zhi-Min Shao, et al. Lapatinib plus capecitabine in treating HER2-positive advanced breast cancer: efficacy, safety, and biomarker results from Chinese patients. Chinese J Cancer, 2011, 30(5): 327-334. 
  20. Shuyang Yao, Binghe Xu*, Qing Li, Pin Zhang, Peng Yuan, Jiayu Wang, Fei Ma, Yan Sun. Goserelin plus letrozole as first- or second-line hormonal treatment in premenopausal patients with advanced breast cancer. Endocrine J, 2011, 58(6): 509-516. 
  21. Binghe Xu*, Zefei Jiang, Sung-Bae Kim,  Shiying Yu, Jifeng Feng, Artur Malzyner,  Auro del Giglio, Hyun C. Chung, Li Jun Shen  Daniel Lee Kay Pen. Biweekly gemcitabine-paclitaxel, gemcitabine-carboplatin, or gemcitabine-cisplatin as first-line treatment in metastatic breast cancer after anthracycline failure: a phase II randomized selection trial. Breast Cancer, 2011, 18: 203-212.
  22. Weihong Zhao, Yongmei Song, Binghe Xu*, and Qimin Zhan. Overexpression of centrosomal protein Nlp confers breast carcinoma resistance to paclitaxel. Cancer Biology & Therapy, 2012, 13(3): 156–163.
  23. Wang J, Xu B*, Yuan P, Zhang P, Li Q, Ma F, Fan Y. TOP2A amplification in breast cancer is a predictive marker of anthracycline-based neoadjuvant chemotherapy efficacy. Breast Cancer Res Treat. 2012 Sep;135(2):531-7.
  24. Valero V, Vrdoljak E, Xu B, Thomas E, Gómez H, Manikhas A, Medina C, Li RK, Ro J, Bosserman L, Vahdat L, Mukhopadhyay P, Opatt D, Sparano JA. Maintenance of clinical efficacy after dose reduction of ixabepilone plus capecitabine in patients with anthracycline- and taxane-resistant metastatic breast cancer: a retrospective analysis of pooled data from 2 phase III randomized clinical trials. Clin Breast Cancer. 2012 Aug;12(4):240-6. 
  25. Ding X, Fan Y, Ma F, Li Q, Wang J, Zhang P, Yuan P, Xu B*. Prolonged administration of bisphosphonates is well-tolerated and effective for skeletal-related events in Chinese breast cancer patients with bone metastasis. Breast. 2012 Aug;21(4):544-9. Epub 2012 May 22.
  26. Wang J, Xu B*, Yuan P, Zhang P, Li Q, Ma F, Fan Y. TOP2A amplification in breast cancer is a predictive marker of anthracycline-based neoadjuvant chemotherapy efficacy. Breast Cancer Res Treat. 2012 Sep;135(2):531-7.

* First or Corresponding author